Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

Published:2019-06-18 Issue:40 Volume:10 Page:4018-4025
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Ang Celina¹,Klempner Samuel J.²,Ali Siraj M.³,Madison Russell³,Ross Jeffrey S.³,Severson Eric A.³,Fabrizio David³,Goodman Aaron⁴,Kurzrock Razelle⁴,Suh James³,Millis Sherri Z.³

Affiliation:

1. Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA

2. Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

3. Foundation Medicine, Cambridge, MA, USA

4. Department of Medicine, Division of Hematology and Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer;BMC Cancer;2024-07-07

3. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy;The Oncologist;2024-06-27

4. Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma;Cancer Biology & Medicine;2024-05-06

5. Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors;Cancer Genomics - Proteomics;2024-04-26